HUTCHMED (China) LtdHCM
What HUTCHMED (China) Ltd does.
We are a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases. Our company started in China in 2000 and has since developed fully integrated capabilities and expanded oncology and immunology drug development operations globally. Our operational achievements and capabilities to date include:
Broad pipeline of differentiated targeted therapies and immunotherapies built for the global market . We have a pipeline of differentiated drug candidates covering both novel and validated targets, including MET, VEGFR, FGFR, CSF-1R, Syk, EZH2, PI3K/PIKK, IDH, ERK, BTK, CD47, SHP2 and menin. The aim of our research is to develop drugs with high selectivity and superior safety profiles, a key benefit of which is that our drug candidates have the potential to be effectively paired with other oncology and immunology therapies at effective dosages with fewer side effects.
Commercially launching products while continuing to discover new assets. In China, three of our internally developed drugs, savolitinib, fruquintinib and surufatinib are commercially available to patients as Orpathys, Elunate and Sulanda, respectively. Fruquintinib is marketed as Elunate in China by HUTCHMED, and as Fruzaqla outside of China by our partner Takeda. Fruzaqla has received approval in 38 countries to date, including the United States in 2023, Europe and Japan in 2024. Reimbursement approvals are progressing in many jurisdictions. To accelerate the availability of our innovative medicines for patients globally, we seek partnerships to commercialize our drugs outside of China, such as our partnership with AstraZeneca on savolitinib and with Takeda on fruquintinib. In addition, we have 15 other drug candidates that have entered clinical development and several pre-clinical drug candidates.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $228.0M | $356.1M | $426.4M | $838.0M | $630.2M | $548.5M |
| Net income | -$125.7M | -$194.6M | -$360.8M | $100.8M | $37.7M | $456.9M |
| Free cash flow | -$70.0M | -$220.6M | -$305.3M | $186.6M | -$17.4M | -$78.8M |
More on HCM.
- HUTCHMED (China) Ltd summary
- HUTCHMED (China) Ltd financial statements
- HUTCHMED (China) Ltd key metrics
- HUTCHMED (China) Ltd health scores and style box
- HUTCHMED (China) Ltd earnings
- HUTCHMED (China) Ltd dividends
- HUTCHMED (China) Ltd valuation
- HUTCHMED (China) Ltd ownership and insiders
- HUTCHMED (China) Ltd peers
Figures from HUTCHMED (China) Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.